SCHEMBL5886930

SCHEMBL5886930

Cc1nc(N2CCN(c3ccc(F)cc3)CC2)nc2c1ccc(=O)n2-c1ccc(C(=O)O)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
RXRA P19793 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
LMNA P02545 3/20 0.41
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
TP53 P04637 2/20 0.41
HTR2C P28335 3/20 0.39
ALDH1A1 P00352 2/20 0.39
HPGD P15428 2/20 0.39
HSD17B10 Q99714 1/20 0.39
HTR2A P28223 1/20 0.39
CFTR P13569 1/20 0.38
CTNNB1 P35222 1/20 0.38
TCF7L2 Q9NQB0 1/20 0.38
MAPK1 P28482 2/20 0.38
MAPT P10636 2/20 0.38
KDM4E B2RXH2 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5886798 0.92 RXRA (0.47) KMT2ARXRASMN1; SMN2LMNANPC1
SCHEMBL5886834 0.91 MEN1 (0.44) MEN1KMT2ASMN1; SMN2LMNANPC1
SCHEMBL5887520 0.91 MEN1 (0.44) MEN1KMT2ASMN1; SMN2LMNANPC1
SCHEMBL5886717 0.87 MEN1 (0.40) MEN1KMT2ASMN1; SMN2LMNANPC1
SCHEMBL5886774 0.87 NPC1 (0.46) MEN1KMT2ARXRANPC1RAB9A
SCHEMBL5887152 0.86 CCNE1 (0.48) NPC1RAB9AHTR2A
SCHEMBL5886728 0.85 CTNNB1 (0.48) LMNATP53CTNNB1TCF7L2MAPT
SCHEMBL5886830 0.84 ALDH1A1 (0.42) MEN1KMT2ARXRASMN1; SMN2LMNA
SCHEMBL5887084 0.84 ALDH1A1 (0.42) MEN1KMT2ARXRASMN1; SMN2LMNA
SCHEMBL5886849 0.82 KDM4E (0.43) MEN1KMT2ARXRASMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7019002-B2 Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents PHARMACIA & UPJOHN, S.P.A. (IT) 2006-03-28 US claimed
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors PHARMACIA ITALIA S.P.A. 2004-01-15 US claimed
US-7019002-B2 Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents PHARMACIA & UPJOHN, S.P.A. (IT) 2006-03-28 US disclosed
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors PHARMACIA ITALIA S.P.A. 2004-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors TERT, TERF2, TERF2IP MEN1 2183/4885KMT2A 1530/4885RXRA 3986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.